Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

• N-methyl-D-aspartate-(NMDA) subtype of ligand-gated ion channel receptors are a diverse family of glutamate receptors widely accepted to mediate synaptic transmission, key mechanisms of synaptic plasticity, and dynamic neuronal network connectivity required for normal nervous system development and function.
• the NMDA receptor is composed of four protein subunits, two GluNl subunits and two GluN2 subunits.
• the GluNl subunit is derived from a single gene (GRIN1), is ubiquitously expressed throughout the nervous system, and is common to all NMDA receptors.
• GluN2A-D Four different GluN2 subunits, GluN2A-D, are derived from separate genes (GRIN2A-D) that are differentially expressed in different regions of the nervous system and by distinct populations of neurons within a particular region.
• a GluN3 subunit has also been identified, but its function is less well understood.
• individual neurons may express more than one GluN2 subunit and individual NMDA receptors expressed by such neurons may contain two of the same GluN2 subunits (for example, 2GluN2B subunits) or two different subunits (one GluN2A and one GluN2B subunit).
• all NMDA receptor subunits are expressed as diverse mRNA splice variants.
• native nervous system NMDA receptors are highly diverse in their composition.
• NMDA receptor-dependent mechanisms of synaptic transmission, plasticity, and neuronal network connectivity are broadly implicated in diseases of the nervous system. Accordingly, compounds that are capable of modulating NMDA receptors may be useful for the treatment of nervous system disorders and diseases, for example, schizophrenia, Alzheimer’s disease, attention deficit and hyperactivity disorder, and autism.
• Compound 1 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2- (3-fluoro-3-methylazetidin-l-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one, having the following structure:
• Compound 1 is a heterocyclic pyrrolopyrimidinone analogue which modulates NMDA receptors (e.g., positive allosteric modulation of NMDA receptors) and may be used for treating psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
• NMDA receptors e.g., positive allosteric modulation of NMDA receptors
• Heterocyclic NMDA receptor modulators have been previously described in e.g., WO 2017/100591.
• WO 2017/100591 a wide range of heterocyclic cores including pyrrolopyrazinones, thienopyridinones, imidazopyrazinones, pyrrolopyridinones, and pyrrolopyrimidinones are disclosed.
• the potency of the compounds in WO 2017/100591 was evaluated on the basis of the compounds’ ability to reverse the suppression of the Ca 2+ response mediated by Ro 25-6981, a potent and selective antagonist of NMDA glutamate receptors containing the NR2B subunit, and 5,7-dichlorokynurenic acid (DCKA), a selective NMDA receptor antagonist acting at the glycine site of the NMDA receptor complex.
• Ro 25-6981 a potent and selective antagonist of NMDA glutamate receptors containing the NR2B subunit
• DCKA 5,7-dichlorokynurenic acid
• Potency in the Ro 25-698 l/DCKA assay was quantified by % response recovered (as shown e.g., in Table 49 of WO 2017/100591) and/or by % maximum measured potentiation. Of the most potent twenty-one analogs exemplified in WO 2017/100591 in the Ro 25-6981/DCKA assay and ranked by % response recovered, none were shown to be pyrrolopyrimidinone analogues.
• Example 181 pyrrolo[2,3-d]pyrimidin-4-one in WO 2017/100591 is Example 181.
• This compound was determined to be the most potent exemplified pyrrolo[2,3-d]pyrimidin-4-one based on the maximum measured potentiation (%) in the Ro 25-698 l/DCKA assay. See Table 1 below for a comparison of Examples 174 and 181 in these two potency readouts from this Ro 25- 698 l/DCKA assay. Similar to the results with Example 174, Compound 1 was again found to be more potent (approximately 2.5-fold) in the disclosed oocyte NR2B PAM potentiation assay. Taking together, these results evidence the clinical potency advantage of Compound 1 over other pyrrolo[2,3-d]pyrimidin-4-one based scaffolds.
• WO 2017/100591 discloses a constitutional isomer of Compound 1 (i.e., Example 436) as well as a one nitrogen variant (i.e., Example 285). Despite these structural similarities, Compound 1 was found to possess superior aqueous solubility, microsomal stability, and/or pharmacokinetic properties as compared to these two compounds. Table 2, for example, shows that Compound 1 has approximately a lO-fold increase in aqueous solubility over Example 436, the constitutional isomer of Compound 1.
• FIG. 1 illustrates the cognitive enhancing effect of oral Compound 1 (0.3, 1.0, and 3.0 mg/kg) against phencyclidine (PCP)-induced cognitive impairment in the rat Novel Object Recognition (NOR) test.
• PCP phencyclidine
• FIG. 2 illustrates the results from Compound 1 in a mismatch negativity efficacy model.
• the terms“subject” and“patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like).
• the subject is a human in need of treatment.
• salts of the compounds refer to non toxic“pharmaceutically acceptable salts.”
• Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
• Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
• Pharmaceutically acceptable acidic/anionic salts include, e.g., the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, carbonate, citrate, dihydrochloride, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, malate, maleate, malonate, mesylate, nitrate, salicylate, stearate, succinate, sulfate, tartrate, and tosylate.
• pharmaceutically acceptable carrier refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
• Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
• ion exchangers alumina, aluminum stearate, lecithin
• serum proteins such as human serum albumin
• buffer substances such as phosphate
• “Pharmaceutically acceptable” means molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
• treatment refers to reversing, alleviating, reducing the likelihood of developing, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
• treatment may be administered after one or more symptoms have developed, i.e., therapeutic treatment.
• treatment may be administered in the absence of symptoms.
• treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors), i.e., prophylactic treatment. Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
• the term“effective amount” or“therapeutically effective amount” includes an amount of a compound described herein that will elicit a biological or medical response of a subject e.g., a dosage of between 0.01 - 100 mg/kg body weight/day.
• PAM refers to“positive allosteric modulator”.
• Compound 1, or a pharmaceutically acceptable salt thereof and compositions described herein are useful in treating diseases and/or disorders associated with the activity of NMD A receptors.
• diseases and/or disorders include e.g., psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
• Compound 1 or a pharmaceutically acceptable salt thereof and compositions described herein are useful for modulating the activity of the NMDA receptor.
• Compound 1 or a pharmaceutically acceptable salt thereof and compositions described herein are useful for treating schizophrenia, Alzheimer’s disease, attention deficit and hyperactivity, autism, and other nervous system-associated conditions.
• Compound 1 or a pharmaceutically acceptable salt thereof and compositions described herein are useful for treating schizophrenia, including positive, negative, and cognitive symptoms.
• Schizophrenia is a debilitating mental disorder encompassing three symptom domains: positive (psychosis, hallucination, delusions), negative (withdrawal), and cognitive (global reduction in cognitive ability).
• Positive symptoms of schizophrenia typically emerge early in adulthood and are treated with antipsychotic medications.
• cognitive deficits are severe, emerge in the adolescent prodromal stage, are resistant to antipsychotic therapy, and are the leading cause of lifetime disability as measured by impaired global function (inability to live independently, unemployment, etc).
• NMDA receptor hypofunction is the leading hypothesis for the cause of schizophrenia.
• Compound 1 or a pharmaceutically acceptable salt thereof and compositions described herein are useful for improving cognitive and global function, and/or preventing the onset of schizophrenia e.g., in people at risk of developing schizophrenia.
• Compound 1 or a pharmaceutically acceptable salt thereof and compositions described herein are useful for treating cognitive and emotional deficits and other symptoms associated with exemplary psychiatric disorders including major depressive disorder, and including but not limited to those suffering from schizoaffective disorder, bipolar disorder, obsessive-compulsive disorder, dysphobic disorder, dysthymic disorder, psychotic depression, post-traumatic stress disorder, and other anxiety disorders.
• Suitable herein are methods of treating attention deficit disorder, ADHD (attention deficit hyperactivity disorder), schizophrenia, anxiety, amelioration of opiate, nicotine and/or ethanol addiction (e.g., method of treating such addiction or ameliorating the side effects of withdrawing from such addiction), spinal cord injury, diabetic retinopathy, traumatic brain injury, and/or post-traumatic stress syndrome in a patient in need thereof, that includes administering Compound 1, or a pharmaceutically acceptable salt thereof, or a composition thereof.
• ADHD attention deficit hyperactivity disorder
• schizophrenia anxiety, amelioration of opiate
• nicotine and/or ethanol addiction e.g., method of treating such addiction or ameliorating the side effects of withdrawing from such addiction
• spinal cord injury diabetic retinopathy
• traumatic brain injury traumatic brain injury
• post-traumatic stress syndrome e.g., post-traumatic stress syndrome
• Compound 1 or a pharmaceutically acceptable salt thereof and compositions described herein are useful for treating cognitive and emotional deficits and other symptoms resulting from neurological diseases, including but not limited to a patient suffering from mild cognitive impairment or any form of dementia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, multiple sclerosis, and seizure disorders.
• Compound 1 or a pharmaceutically acceptable salt thereof and compositions described herein are useful for treating dysfunction caused by
• neurodevelopmental disorders e.g., abnormal brain development, including but not limited to Rett Syndrome, Attention Deficit and Hyperactivity Disorder, autism and autism spectrum disorders such as Phelan-McDermid Syndrome, and other forms of intellectual disability such as Fragile X syndrome, tuberous sclerosis, Smith-Lemli-Opitz Syndrome, Down syndrome and childhood epilepsies or epilepsy/aphasia spectrum disorders such as Benign partial Epilepsy of childhood with CentroTemporal Spikes (BECTS) or Landau- Kleffner Syndrome (LKS).
• BECTS CentroTemporal Spikes
• LLS Landau- Kleffner Syndrome
• a method is also provided to treat patients suffering from abnormal brain function resulting from infections of the central nervous system, exposure to toxic agents or other xenobiotics or naturally occurring toxins, and/or autoimmune disorders including, but not limited to anti- NMD A receptor encephalitis.
• Compound 1 or a pharmaceutically acceptable salt thereof and compositions described herein are useful for treating subjects having NMDA receptor hypofunction.
• a method of treating a subject having a disease, disorder, or condition described herein comprising administering to the subject a therapeutically effective amount of Compound 1, or a pharmaceutically acceptable salt thereof, or a composition thereof.
• Compound 1 or a pharmaceutically acceptable salt thereof, or a composition thereof, for the manufacture of a medicament for treating a disease, disorder, or condition described herein.
• Compound 1 or a pharmaceutically acceptable salt thereof, or a composition thereof, for use in treating a disease, disorder, or condition described herein.
• compositions comprising Compound 1; and a pharmaceutically acceptable carrier. These compositions can be used to treat one or more of the diseases, disorders, and conditions described above.
• compositions may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
• parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra- synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
• Liquid dosage forms, injectable preparations, solid dispersion forms, and dosage forms for topical or transdermal administration of a compound are included herein.
• compositions may be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the provided compound, such as e.g., 0.1 - 100 mg/kg body weight/day, can be administered to a patient receiving these compositions.
• a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the particular disease being treated.
• the amount of a provided compound in the composition will also depend upon the particular compound in the composition.
• Combination therapies using a therapeutically effective amount of Compound 1, or a pharmaceutically acceptable salt thereof, and an effective amount of one or more additional pharmaceutically active agents is also included herein.
• Compound 1, or a pharmaceutically acceptable salt thereof, and an effective amount of one or more atypical antipsychotics is also included herein.
• Atypical antipsychotics include, e.g., lurasidone, quetiapine, olanzapine, asenapine, risperidone, ziprasidone, clozapine, mel perone, cariprazine, aripiprazole, pimavanserin, ITI-007, RP506, and remoxipride.
• Step-1 Preparation of 4,6-dichloro-5-(2,2-diethoxyethyl)pyrimidine (2):
• Step-2 Preparation of 4-chloro-7-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidine (3):
• Step-3 Preparation of 7-cyclopropyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (4):
• Step-4 Preparation of ethyl 2-(7-cyclopropyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3- d]pyrimidin-3-yl)acetate (5):
• Step-5 Preparation of ethyl 2-(5-bromo-7-cyclopropyl-4-oxo-4,7-dihydro-3H- pyrrolo[2,3-d]pyrimidin-3-yl)acetate (6):
• Step-6 Preparation of 2-(5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-4-oxo-4,7-dihydro- 3H-pyrrolo[2,3-d]pyrimidin-3-yl)acetic add (7):
• Step-7 Preparation of 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3- methylazetidin-l-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one:
• Step 3 Synthesis of 5-bromo-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-l-yl)-2- oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 13
• Step 4 Synthesis of 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3- methylazetidin-l-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
• Compound 1 is a potent positive allosteric modulator across all of the NR2A, NR2B, NR2C and NR2D NMDA subtypes.
• EC50 refers to the concentration of a compound that gives half-maximal response.
• EC50 refers to the concentration of a compound that gives half-maximal response.
• Example 174 the most potent exemplified compound tested in the Ro 25-698 l/DCKA assay quantified by % response recovered
• Example 181 the most potent exemplified compound tested in the Ro 25-698 l/DCKA assay quantified by % maximum measured potentiation.
• Compound 1 is approximately three-fold and 2.5-fold more potent in the oocyte NR2B PAM potentiation assay than Example 174 and Example 181, respectively. This improvement is advantageous because higher potency in the oocyte NR2B PAM potentiation assay is, in one aspect, anticipated to provide enhanced therapeutic benefit in humans.
• Example 436 of WO 2017/100591 a constitutional isomer (imidazopyrazinone core) of Compound 1 which demonstrated potency (100% response recovered) in the Ro 25-698 l/DCKA assay.
• the aqueous solubility of the test compound was determined in phosphate buffer saline, pH 7.4, measured by shake-flask method. In this assay, DMSO stock solution of test compound was added to buffer followed by equilibration (shaking), filtration, and determination of soluble amount by HPLC-UV.
• Monolayer systems consist of a tight cell layer grown on a porous support to separate two fluid compartments. They are widely regarded as the most sophisticated in vitro tools for medium to high throughput modeling of important pharmacokinetic barriers, such as intestinal epithelium, blood-brain barrier, etc. (J Pharm Sci 2012 Apr; 101(4): 1337-1354). Two systems that are applied widely in monolayer studies are the human colon carcinoma cell line Caco-2 and MDR1 -transfected MDCKII and LLC-PK1 cells. In monolayer assays, the flux of a compound through the monolayer of cells is measured.
• the unidirectional flux of the compound of interest is determined by applying it to either the apical or to the baso lateral side of the cell layer and monitoring the time resolved redistribution of it between the two compartments.
• the vectorial transport ratio (often referred to as Efflux Ratio) is determined by applying bidirectional measurements [apical-to-basolateral (A-B) and basolateral-to-apical (B-A)j.
• Efflux Ratio is determined by applying bidirectional measurements [apical-to-basolateral (A-B) and basolateral-to-apical (B-A)j.
• a ratio higher than 2 or lower than 0.5 indicates the contribution of an active transport process to the net flux of a compound. In the absence of such transport processes this ratio is approximately 1.
• Compound 1 penetrates membranes well and is not subject to efflux in the MDCK efflux assay.
• the liver is the most important site of drug metabolism in the body.
• Liver microsomes are subcellular fractions which contain membrane bound drug metabolizing enzymes. Microsomes can be used to determine the in vitro intrinsic clearance of a compound. The use of species-specific microsomes can be used to enable an understanding of interspecies differences.
• Compound 1 demonstrates good stability in Human Liver Micro somes (HLM) and excellent stability in Rat Liver Microsomes (RLM).
• Compound 1 also exhibited improved in vitro microsomal stability and in vivo clearance in the rat IV pharmacokinetic study. As shown below, the in vivo clearance of Compound 1 is significantly lower than that of structurally-related NMDA PAMs exemplified in WO 2017/100591 for which IV rat clearance data is available. Of particular note is Example 285, a pyrrolopyridinone analog which demonstrated excellent potency in the Ro 25-698 l/DCKA assay and is exceptionally structurally similar to Compound 1. Rat microsomal stability data is provided as well. These improvements in in vitro and in vivo clearance are advantageous because reduced clearance, in one aspect, is anticipated to provide enhanced in vivo performance in humans.
• Rats were treated twice daily for 7 days with either saline vehicle (control group) or PCP (5 mg/kg, intraperitoneal). Following a l4-day washout period of no treatment, rats were tested in the NOR paradigm. Briefly, testing involves two sessions (Tl and T2), each lasting 3 minutes, 1 hour apart. Vehicle or Compound 1 were administered prior to the Tl trial. In Tl, rats are placed in a test arena with two identical objects and allowed to freely explore while their time spent exploring each object is recorded. In T2, rats are returned to the test arena where one of the objects remains the same and the other has been replaced with a novel object. The time spent exploring the novel object versus the time spent exploring the familiar object are recorded and compared to Tl object exploration times.
• Pathophysiological biomarkers of NMDA receptor hypofunction in schizophrenia include EEG measurements of early auditory processing events, such as“Mismatch
• Negativity an EEG Event-Related Potential (ERP) that measures pre-attentional auditory novelty detection.
• MMN is a translatable measure of auditory novelty detection in rats and humans, and is correlated with cognitive and global function in patients with schizophrenia.
• NMDA receptor antagonists PCP, MK-801, and ketamine elicit acute deficits in MMN in rats (all three NMDAr antagonists) and human subjects (ketamine).
• Rats implanted with frontal EEG electrodes were presented with different audio stimuli comprising an auditory oddball“flip-flop” protocol. Briefly, 1,000 standard tones of 6.0kHz were delivered at 90% probability, and 100 deviant tones of 8.0kHz were delivered at 10% probability in pseudo-random order (the flip sequence), and then this sequence was then repeated with the 8 kHz tone as the standard, and the 6 kHz tone as the deviant (the flop sequence).
• MMN is calculated as a difference potential obtained by subtracting the averaged 8 kHz standard tone response (flop) from the averaged 8 kHz deviance tone response (flip) at each 1 ms time point over the EEG recording epochs from 50 ms prior to 150 ms after the onset of these 50 ms auditory tones.
• mice were dosed with vehicle or Compound 1 (60 mg/kg) twice, 4 hours apart. Rats were then dosed with saline control or MK-801 (0.2 mg/kg, IP) immediately prior to test sessions. Test sessions were comprised of three 20-minute flip- flop blocks. As shown by FIG. 2, administration of vehicle plus MK-801 significantly impaired MMN compared to administration of vehicle plus saline.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Psychiatry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Hospice & Palliative Care (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Steroid Compounds (AREA)
• Pyridine Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (30)

Applications Claiming Priority (2)

Publications (2)

Family

ID=69228330

Family Applications (1)

Country Status (37)

Cited By (1)

Families Citing this family (4)

Citations (1)

Family Cites Families (67)

• 2019
  • 2019-08-02 BR BR112021001967-7A patent/BR112021001967A2/pt unknown
  • 2019-08-02 RS RS20230563A patent/RS64359B1/sr unknown
  • 2019-08-02 FI FIEP19876025.8T patent/FI3830092T3/fi active
  • 2019-08-02 LT LTEPPCT/US2019/044814T patent/LT3830092T/lt unknown
  • 2019-08-02 EP EP23165151.4A patent/EP4223760B1/en active Active
  • 2019-08-02 DK DK19876025.8T patent/DK3830092T3/da active
  • 2019-08-02 CR CR20210125A patent/CR20210125A/es unknown
  • 2019-08-02 US US16/530,274 patent/US10584131B2/en active Active
  • 2019-08-02 SI SI201930580T patent/SI3830092T1/sl unknown
  • 2019-08-02 MA MA53351A patent/MA53351B1/fr unknown
  • 2019-08-02 PL PL19876025.8T patent/PL3830092T3/pl unknown
  • 2019-08-02 CA CA3108519A patent/CA3108519A1/en active Pending
  • 2019-08-02 AU AU2019368147A patent/AU2019368147B2/en active Active
  • 2019-08-02 ES ES23165151T patent/ES3039982T3/es active Active
  • 2019-08-02 CU CU2021000013A patent/CU24647B1/es unknown
  • 2019-08-02 AR ARP190102209A patent/AR115905A1/es not_active Application Discontinuation
  • 2019-08-02 IL IL280474A patent/IL280474B2/en unknown
  • 2019-08-02 CN CN201980051645.9A patent/CN112513047B/zh active Active
  • 2019-08-02 HU HUE19876025A patent/HUE062566T2/hu unknown
  • 2019-08-02 JO JOP/2021/0020A patent/JOP20210020A1/ar unknown
  • 2019-08-02 EA EA202190431A patent/EA202190431A1/ru unknown
  • 2019-08-02 WO PCT/US2019/044814 patent/WO2020086136A2/en not_active Ceased
  • 2019-08-02 TW TW108127473A patent/TWI833783B/zh active
  • 2019-08-02 HR HRP20230774TT patent/HRP20230774T1/hr unknown
  • 2019-08-02 PE PE2021000151A patent/PE20210948A1/es unknown
  • 2019-08-02 ES ES19876025T patent/ES2951872T3/es active Active
  • 2019-08-02 EP EP19876025.8A patent/EP3830092B1/en active Active
  • 2019-08-02 JP JP2021529249A patent/JP7319369B2/ja active Active
  • 2019-08-02 PT PT198760258T patent/PT3830092T/pt unknown
  • 2019-08-02 KR KR1020217006300A patent/KR102797968B1/ko active Active
  • 2019-08-02 MX MX2021001367A patent/MX2021001367A/es unknown
  • 2019-08-02 SG SG11202101125VA patent/SG11202101125VA/en unknown
  • 2019-11-08 US US16/678,806 patent/US10752633B2/en active Active
• 2021
  • 2021-02-01 PH PH12021550242A patent/PH12021550242A1/en unknown
  • 2021-02-02 DO DO2021000025A patent/DOP2021000025A/es unknown
  • 2021-02-03 CL CL2021000294A patent/CL2021000294A1/es unknown
  • 2021-02-12 US US17/174,826 patent/US11542264B2/en active Active
  • 2021-02-25 ZA ZA2021/01273A patent/ZA202101273B/en unknown
  • 2021-03-03 EC ECSENADI202114902A patent/ECSP21014902A/es unknown
  • 2021-03-03 CO CONC2021/0002898A patent/CO2021002898A2/es unknown
• 2023
  • 2023-07-13 US US18/221,694 patent/US20240199617A1/en active Pending
  • 2023-08-02 CY CY20231100387T patent/CY1126144T1/el unknown
• 2024
  • 2024-02-29 US US18/591,531 patent/US20250034145A1/en active Pending

Patent Citations (1)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events